Compare REFR & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | CCEL |
|---|---|---|
| Founded | 1965 | 1989 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Multi-Sector Companies | Managed Health Care |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 29.6M |
| IPO Year | 1995 | 2022 |
| Metric | REFR | CCEL |
|---|---|---|
| Price | $0.87 | $3.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.9K | 9.5K |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $1,488,642.00 | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $354.00 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.82 | $2.72 |
| 52 Week High | $2.70 | $5.52 |
| Indicator | REFR | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 49.49 |
| Support Level | $0.82 | $3.18 |
| Resistance Level | $1.03 | $3.57 |
| Average True Range (ATR) | 0.05 | 0.30 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 23.63 | 17.39 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.